Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2024-05-07

Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating difelikefalin for pruritus in advanced chronic kidney disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KORSUVA (Difelikefalin)

Snippet

Sponsor: Cara Therapeutics, Inc. | Conditions: Chronic Kidney Diseases, Pruritus | Phase 3 | Status: TERMINATED